Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Nature Communications|August 25, 2022
Selective suppression of melanoma lacking IFN-γ pathway by JAK inhibition depends on T cells and host TNF signalingHongxing Shen, Fengyuan Huang, Xiangmin Zhang, et al.
JCO Precision Oncology|February 8, 2023
Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR StudyEddy S Yang, Susan Halabi, Michael Rothe, et al.
International Journal of Cancer|August 24, 2019
Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristicsWendy Demark-Wahnefried, Laura Q Rogers, Justin T Gibson, et al.
Clinical Genitourinary Cancer|April 15, 2015
Effect of African-American Race on Tumor Recurrence After Radical Cystectomy for Urothelial Carcinoma of the BladderRavi K Paluri, Charity J Morgan, David J Mooney, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 12, 2021
A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinomaEddy S Yang, Eric Deutsch, Altan Mehmet, et al.
Oncotarget|September 17, 2017
Implementation and utilization of the molecular tumor board to guide precision medicineShuko Harada, Rebecca Arend, Qian Dai, et al.
Plos One|August 31, 2016
Kinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic TargetsPooja Ghatalia, Eddy S Yang, Brittany N Lasseigne, et al.
International Journal of Oncology|December 20, 2014
Targeting the effector domain of the myristoylated alanine rich C-kinase substrate enhances lung cancer radiation sensitivityTimothy D Rohrbach, John S Jarboe, Joshua C Anderson, et al.
Nature Cancer|February 5, 2022
RNF2 ablation reprograms the tumor-immune microenvironment and stimulates durable NK and CD4+ T-cell-dependent antitumor immunityZhuo Zhang, Lin Luo, Chuan Xing, et al.
Breast Cancer Research : BCR|March 5, 2021
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancerErica M Stringer-Reasor, Jori E May, Eva Olariu, et al.
Pageof 13